ライフサイエンスコーパス: voriconazole

1 , liposomal amphotericin B, caspofungin, and voriconazole).

2 ment groups (P < .001 for all comparisons vs voriconazole).

3 received itraconazole and 19 (10%) received voriconazole.

4 d by the methylation of the antifungal agent voriconazole.

5 ns and long-term antifungal prophylaxis with voriconazole.

6 drug-drug interactions than those noted with voriconazole.

7 of isavuconazole was noninferior to that of voriconazole.

8 viation) of 75 (54) days after initiation of voriconazole.

9 among patients with periostitis who received voriconazole.

10 es are not commonly reported side effects of voriconazole.

11 petitively inhibited by posaconazole but not voriconazole.

12 nt with undetectable trough plasma levels of voriconazole.

13 ntually, all patients were treated with oral voriconazole.

14 improved 3-month visual acuity compared with voriconazole.

15 ll 5 patients receiving primary therapy with voriconazole.

16 ely observed in patients receiving long-term voriconazole.

17 mal levels in hematologic patients receiving voriconazole.

18 a CrCl <50 mL/min and were treated with oral voriconazole.

19 atus isolates with reduced susceptibility to voriconazole.

20 results was 99.6% for both posaconazole and voriconazole.

21 inical breakpoints for both posaconazole and voriconazole.

22 ents, and 154 (79%) patients were started on voriconazole.

23 e, and to the triazole drugs fluconazole and voriconazole.

24 concluded that they could not recommend oral voriconazole.

25 69) and amphotericin (0.70) and moderate for voriconazole (0.60), and the Pearson correlation of MICs

26 y MIC50 and MIC90 values were determined for voriconazole (1 and 2 mug/ml, respectively), itraconazol

27 al was designed to randomize 368 patients to voriconazole (1%) or natamycin (5%), applied topically e

28 mL), fluconazole (36.9 +/- 30.7 mug/mL), and voriconazole (1.9 +/- 2.9 mug/mL) are reported.

29 a placebo (all participants received topical voriconazole, 1%).

30 All patients received topical voriconazole, 1%, and after the results of the Mycotic U

31 All participants received topical voriconazole, 1%, and natamycin, 5%.

32 rticipants were randomly assigned to topical voriconazole, 1%, or topical natamycin, 5%.

33 0.02%, hexamidine diisethioonate, 0.1%, and voriconazole, 1.0%, were effective in completely killing

34 ody weight orally [p.o.] twice a day [BID]), voriconazole (10 mg/kg p.o. BID), liposomal amphotericin

35 alysis of physicochemical characteristics of voriconazole (10 mg/mL) and posaconazole (6, 12 mg/mL) s

36 ng patients not treated with itraconazole or voriconazole, 194 patients remained.

37 1 to 21 mm), posaconazole (28 to 35 mm), and voriconazole (25 to 33 mm); and C. krusei, amphotericin

38 as determined for fluconazole (21 isolates), voriconazole (28 isolates), amphotericin (29 isolates),

39 8 to 26 mm), posaconazole (28 to 38 mm), and voriconazole (29 to 39 mm).

40 e daily); and group 4, AmB (0.7-1 mg/kg) and voriconazole (300 mg twice daily).

41 amphotericin B, 430 mg daily, but changed to voriconazole, 300 mg twice daily, secondary to renal ins

42 erapy (n = 20) or intrastromal injections of voriconazole 50 mug/0.1 ml (n = 20).

43 ith isavuconazole (48 patients) and 20% with voriconazole (52 patients), with an adjusted treatment d

44 able 12-week response rate was obtained with voriconazole (54.7%) than with AmB (29.9%) (P < .0001).

45 ither intravenously or orally once daily) or voriconazole (6 mg/kg intravenously twice daily on day 1

46 d a CrCl <50 mL/min and received intravenous voriconazole, 77 (46.4%) had a CrCl >/=50 mL/min and rec

47 apy of fluconazole (60%), caspofungin (24%), voriconazole (8%), or liposomal amphotericin B (5%).

48 mphigus vulgaris responded to treatment with voriconazole, 8 mg/kg/d, for 24 days.

49 esistance to fluconazole and elevated MIC to voriconazole (81%), amphotericin B (61%), flucytosine (5

50 f 1.8-line improvement with natamycin versus voriconazole (95% confidence interval 0.5-3.0, P = 0.006

51 In contrast, voriconazole, a CYP46A1 inhibitor, was severely toxic ev

52 C results obtained for both posaconazole and voriconazole after only 24 h of incubation may be used t

53 micafungin, anidulafungin, fluconazole, and voriconazole against Candida species and compared resist

54 values for isavuconazole, posaconazole, and voriconazole against Candida spp. were 0.5, 1, and 0.25

55 48-h MIC determinations of posaconazole and voriconazole against more than 16,000 clinical isolates

56 The pharmacodynamics of voriconazole against wild-type and 3 resistant strains o

57 istic interactions with both fluconazole and voriconazole against ~89% of the tested strains (SigmaFI

58 In a Cox regression model, exposure to voriconazole alone (adjusted hazard ratio 2.39, 95% conf

59 Eyes treated with oral voriconazole also had a mean 0.29 decreased logMAR (impr

60 ve role under glaucomatous conditions, while voriconazole, an antifungal drug, is retinotoxic.

61 Nineteen patients receiving topical voriconazole and 16 patients who were given intrastromal

62 ine patients started treatment (32 receiving voriconazole and 27 receiving placebo) and were included

63 Of these, 33 (45.8%) were randomized to oral voriconazole and 39 (54.2%) to placebo.

64 ; 3.4 um, 2.4, 78%; and 3.0 um, 2.3, 79% for voriconazole and 6, 12 mg/mL of posaconazole, respective

65 Fusarium isolates were least susceptible to voriconazole and A flavus isolates were least susceptibl

66 IA were randomly assigned to treatment with voriconazole and anidulafungin or placebo.

67 ium species isolates had the highest MICs to voriconazole and Aspergillus flavus isolates had the hig

68 pediatric patients treated with combination voriconazole and caspofungin (V/C) salvage therapy for r

69 in the pediatric population with concurrent voriconazole and caspofungin therapy.

70 rystal structures of CYP46A1 in complex with voriconazole and clotrimazole, and in the present work w

71 x with other drugs, including the antifungal voriconazole and clotrimazole.

72 le, fluconazole, itraconazole, ketoconazole, voriconazole and ketaminazole bound tightly to CYP51 (Kd

73 ntrast, fluconazole did not bind to CYP5218, voriconazole and ketaminazole bound weakly (Kd ~107 and

74 Minimum inhibitory concentration of voriconazole and natamycin in baseline cultures.

75 nfidence interval 1.31-4.37) and exposure to voriconazole and other azole(s) (adjusted hazard ratio 3

76 n analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependen

77 was no association between susceptibility to voriconazole and outcome.

78 Between the voriconazole and placebo groups, there were no significa

79 Voriconazole and posaconazole MICs were 0.5-4 and 0.06-0

80 rm the ability of the Etest method to detect voriconazole and posaconazole resistance among Aspergill

81 conazole-induced transaminitis with systemic voriconazole and progression of IA after switching to or

82 in vitro showed mostly high MICs, except for voriconazole and the echinocandins.

83 ition, and x-ray structure in complexes with voriconazole and the experimental inhibitor (R)-N-(1-(2,

84 Fifteen continued to receive voriconazole, and 10 were switched to amphotericin B.

85 a CrCl >/=50 mL/min and received intravenous voriconazole, and 47 (28.3%) had a CrCl <50 mL/min and w

86 2 and May 2013 for agreement of fluconazole, voriconazole, and amphotericin B susceptibility results

87 cin compared with those randomly assigned to voriconazole, and especially among patients with Fusariu

88 ate from the patient was more susceptible to voriconazole, and hence aerosolized voriconazole was int

89 tericin B, intravitreal amphotericin B, oral voriconazole, and intravitreal voriconazole occurred in

90 The species has a higher amphotericin B, voriconazole, and itraconazole MIC and causes more chron

91 clinical breakpoints (CBPs) for fluconazole, voriconazole, and the echinocandins have been revised to

92 le, itraconazole, fluconazole, posaconazole, voriconazole, and the three echinocandins were assessed

93 BSI isolates of C. glabrata to fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin

94 amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, an

95 th high-dose, long-term, orally administered voriconazole appeared to achieve better outcomes in trea

96 Susceptibility to voriconazole appeared to decrease during the relatively

97 ogenous fungal endophthalmitis, intravitreal voriconazole appears to provide the broadest spectrum of

98 Potential CLSI breakpoints for voriconazole are </= 0.5 mg/L for susceptible and >1 mg/

99 Potential EUCAST breakpoints for voriconazole are </=1 mg/L for susceptible and >2 mg/L f

100 aconazole), 98.4% (posaconazole), and 99.6% (voriconazole) assessing EA at +/-2 dilutions and 99.6% (

101 the current data and potential mechanisms of voriconazole-associated photosensitivity and carcinogene

102 ize the natural history of these potentially voriconazole-associated tumors, a nationwide call for no

103 of Optisol-GS were supplemented with either voriconazole at 1x, 10x, 25x, or 50x minimum inhibitory

104 aconazole), 87.7% (posaconazole), and 96.3% (voriconazole) at +/-1 dilution.

105 rns or young infants, as the under-dosage of voriconazole based on adult data revealed.

106 ause mortality, whereas the initial use of a voriconazole-based regimen showed a protective effect (H

107 Glucose has a higher affinity to bind with voriconazole by hydrogen bonding and decrease the suscep

108 methods for itraconazole, posaconazole, and voriconazole by testing 245 Aspergillus clinical isolate

109 to oral isavuconazole (isavuconazole arm) or voriconazole (caspofungin arm).

110 Voriconazole, caspofungin, and combination antifungals w

111 netrating keratoplasty (PK); amphotericin B, voriconazole, caspofungin, and combination therapy; and

112 triazole antifungal agents, itraconazole and voriconazole, causing neuropathy.

113 od volume variation and also to quantify the voriconazole concentration for 26 patients undergoing vo

114 netic resonance imaging (MRI), serum and CSF voriconazole concentrations, and clinician assessment of

115 Voriconazole could be a good choice for treating corneal

116 The addition of caspofungin and voriconazole decreased growth of Candida in a species-de

117 MUTT II showed that oral voriconazole did not improve outcomes overall, although

118 001), alkaline phosphatase (P = .020), daily voriconazole dose (P < .001), and cumulative voriconazol

119 voriconazole dose (P < .001), and cumulative voriconazole dose (P = .027) were significantly elevated

120 tive infections repeatedly required profound voriconazole dose reductions whenever high-dose meropene

121 Moreover, treatment with voriconazole due to the Aspergillus flavus and meropenem

122 d best in testing amphotericin B (EA, 100%), voriconazole (EA, 93.7%), and posaconazole (EA, 94.8%) a

123 combination of all five lead compounds with voriconazole exhibited either synergistic or additive ef

124 conazole resistant in vitro, fluconazole and voriconazole exhibited significantly higher MICs against

125 Patients receiving oral voriconazole experienced a total of 58 adverse events (4

126 Voriconazole exposure decreased mortality in 2002-2011 (

127 ports describing skin cancer associated with voriconazole exposure emerged shortly after US Food and

128 atients treated with the same formulation of voriconazole for a minimum of 3 consecutive days were in

129 ) for natamycin were equal to or higher than voriconazole for all organisms except Curvularia species

130 Patients who received voriconazole for at least 1 month for probable or confir

131 Of 114 patients who were off voriconazole for at least 3 months, hair loss had stoppe

132 center trial comparing topical natamycin and voriconazole for fungal keratitis treatment.

133 a benefit of topical natamycin over topical voriconazole for fungal ulcers, particularly among those

134 eutic experience with the use of aerosolized voriconazole for IA in a lung transplant patient.

135 Survival was higher for voriconazole for mycologically documented (probable/prov

136 Isavuconazole was non-inferior to voriconazole for the primary treatment of suspected inva

137 of monotherapy with topical natamycin versus voriconazole for the treatment of fungal keratitis.

138 linical trial comparing topical natamycin or voriconazole for treating filamentous fungal keratitis.

139 .6%), anidulafungin (from 0.9% to 7.3%), and voriconazole (from 6.1% to 18.4%) against Candida glabra

140 ment was significantly better in the topical voriconazole group (P = 0.008).

141 conazole group and 6 patients (31.6%) in the voriconazole group.

142 Fusarium ulcers randomized to oral voriconazole had a 0.43-fold decreased hazard of perfora

143 Patients on voriconazole had a statistically significant increase in

144 about reversal of hair loss were asked after voriconazole had been stopped for at least 3 months.

145 neral, of the eight antifungal drugs tested, voriconazole had the greatest in vitro activity, while a

146 eiving isavuconazole and 255 [98%] receiving voriconazole) had treatment-emergent adverse events (p=0

147 Studies consistently suggest that voriconazole has a limited role in the treatment of fila

148 tested, we demonstrate that tioconazole and voriconazole have the greatest overall inhibition for al

149 and 16 patients who were given intrastromal voriconazole healed with therapy.

150 tioconazole, as well as the first example of voriconazole heme iron ligation through a pyrimidine nit

151 he emergence and geographical migration of a voriconazole highly resistant A. fumigatus that was asso

152 ght to determine whether a 3-month course of voriconazole improved asthma-related outcomes in patient

153 was compared to caspofungin followed by oral voriconazole in a Phase 3, randomized, double-blind, mul

154 Voriconazole in histoplasmosis was associated with incre

155 efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease.

156 eficial effect of 3 months of treatment with voriconazole in patients with moderate-to-severe asthma

157 he current data regarding the implication of voriconazole in the development of skin cancer in organ

158 physicians should consider prescribing oral voriconazole in these cases.

159 The mechanism of voriconazole-induced skin cancer is still unknown and ma

160 ve aspergillosis (IA) manifested symptoms of voriconazole-induced transaminitis with systemic voricon

161 Through GCMS, we demonstrate that voriconazole inhibits 14alpha-demethylase as treatment i

162 iconazole involvement, the mean time between voriconazole initiation and SCC diagnosis was 39 +/- 18

163 Intrastromal voriconazole injections showed a 2.85-fold increased haz

164 A multidisciplinary committee evaluated voriconazole involvement in each case.

165 The committee determined the likelihood of voriconazole involvement to be high in 15 cases, interme

166 atients with high/intermediate likelihood of voriconazole involvement, the mean time between voricona

167 Voriconazole is a first-line agent for the treatment of

168 Voriconazole is a triazole antifungal medication used fo

169 Voriconazole is a widely prescribed antifungal medicatio

170 AmB plus voriconazole is an effective alternative combination in

171 of the drug, and it is now established that voriconazole is an independent risk factor for the devel

172 The cytochrome P450 51 (CYP51) inhibitor voriconazole is currently the drug of choice, yet the tr

173 tion should be sought, as discontinuation of voriconazole is effective at reversing the disease.

174 Voriconazole is increasingly used as treatment for histo

175 ugs that are used systemically (fluconazole, voriconazole, ketoconazole, itraconazole, and posaconazo

176 Serum voriconazole levels varied, and CSF concentrations of vo

177 receive oral voriconazole vs oral placebo; a voriconazole loading dose of 400 mg was administered twi

178 Voriconazole long-term therapy is suspected to induce cu

179 ill incidence rate, 40% [6 of 15 isolates]), voriconazole (median growth grade, 2.0; kill incidence r

180 entration was elevated in patients receiving voriconazole (median, 156.5 mug/L; interquartile range,

181 30 muM 24(S)-HC was required to prevent the voriconazole-mediated retinal damage.

182 Among voriconazole-treated cases, the voriconazole MIC did not correlate with any of the measu

183 azole, of which 98.8% were nonsusceptible to voriconazole (MIC > 0.5 mug/ml) and 9.3%, 9.3%, and 8.0%

184 similar to previous reports except that the voriconazole MIC90 against Aspergillus species was 2-fol

185 ase per year (95% CI, 1.13-4.56; P = .02) in voriconazole MICs after controlling for the infectious o

186 121F/T289A isolates were highly resistant to voriconazole (minimum inhibitory concentration >/=16 mg/

187 Compared with voriconazole monotherapy, combination therapy with anidu

188 nown and may involve its primary metabolite, voriconazole N-oxide.

189 atients with hematologic malignancies taking voriconazole (n = 20), posaconazole (n = 8), and itracon

190 ricin B, oral voriconazole, and intravitreal voriconazole occurred in 34.8%-43.5%, 0-8.3%, 68.8%, 69.

191 To explore the role of adjuvant oral voriconazole on clinical outcomes in Fusarium keratitis.

192 or worse and were randomized to receive oral voriconazole or a placebo (all participants received top

193 possible IA in patients treated with either voriconazole or AmB.

194 to either receive intrastromal injection of voriconazole or topical therapy alone.

195 01), fluconazole use within 30 days prior to voriconazole (OR, 6.21; P = .008), coadministration of p

196 unger than 13 years of age, an echinocandin, voriconazole, or itraconazole is suggested.

197 m; cyclosporine; ketoconazole, itraconazole, voriconazole, or posaconazole; and dronedarone.

198 ne; fluconazole; ketoconazole, itraconazole, voriconazole, or posaconazole; cyclosporine; erythromyci

199 pisodes and confirmed the higher efficacy of voriconazole over AmB deoxycholate in mycologically docu

200 eiving isavuconazole and 155 (60%) receiving voriconazole (p<0.001).

201 eloped that enabled simulation of human-like voriconazole pharmacokinetics.

202 azole, or amphotericin; newer triazoles (ie, voriconazole, posaconazole) have been demonstrated to be

203 ive concentrations (MECs) of amphotericin B, voriconazole, posaconazole, caspofungin, and micafungin

204 ifungal agents (amphotericin B, fluconazole, voriconazole, posaconazole, caspofungin, anidulafungin,

205 Voriconazole, posaconazole, itraconazole, amphotericin B

206 Our results suggest that long-term voriconazole prescription may be associated with a multi

207 heoretical docking studies demonstrated that voriconazole presented three important hydrogen bonds an

208 ons (IMIs) that occur during posaconazole or voriconazole prophylaxis are rare complications for whic

209 treatment with vancomycin, levofloxacin, and voriconazole prophylaxis resulted in no further infectio

210 The complex with voriconazole provides an explanation for the potency of

211 cases fared better with natamycin than with voriconazole (regression coefficient=0.41 logMAR; 95% CI

212 The intravenous use of voriconazole requires coadministration with sulphobutyle

213 Voriconazole resistance was associated with an excess ov

214 ompared with voriconazole-susceptible cases, voriconazole resistance was associated with an increase

215 s, a 19% lower survival rate was observed in voriconazole-resistant cases at day 42 (P = .045).

216 n patients with voriconazole-susceptible and voriconazole-resistant IA.

217 Of 196 patients with IA, 37 (19%) harbored a voriconazole-resistant infection.

218 I results for fluconazole, posaconazole, and voriconazole, respectively, for each species: 98.9%, 93.

219 s mug/ml) for fluconazole, posaconazole, and voriconazole, respectively, were as follows: 0.12, 0.06,

220 PC945 and either basolateral posaconazole or voriconazole resulted in a synergistic interaction with

221 Discontinuation or dose reduction of voriconazole resulted in improvement of pain in 89% of p

222 Voriconazole route of administration and baseline renal

223 Topical voriconazole seems to be a useful adjunct to natamycin i

224 Discontinuation of voriconazole should be strongly considered in patients e

225 Voriconazole should not be used as monotherapy in filame

226 reatment with PC945, but not posaconazole or voriconazole, showed superior effects to single prophyla

227 The trifluorinated molecular structure of voriconazole suggests a possible link between excess flu

228 albicans and C glabrata was observed in all voriconazole-supplemented vials.

229 a rapid and easy method for fluconazole and voriconazole susceptibility testing for timely tailoring

230 od M27-A3 for fluconazole, posaconazole, and voriconazole susceptibility testing of 1,056 isolates of

231 ducted to compare mortality in patients with voriconazole-susceptible and voriconazole-resistant IA.

232 Compared with voriconazole-susceptible cases, voriconazole resistance

233 were comparable to those of posaconazole and voriconazole; the MIC90 values for isavuconazole, posaco

234 acute phototoxicity during the first year of voriconazole therapy (mean time, 6 months [range, 0-18 m

235 were randomized to receive either topical 1% voriconazole therapy (n = 20) or intrastromal injections

236 All were started on voriconazole therapy alone.

237 Cumulative mean duration of voriconazole therapy at SCC diagnosis was 35 months (ran

238 as conducted among 195 patients who received voriconazole therapy at St Joseph Mercy Hospital during

239 were common adverse effects associated with voriconazole therapy during the multistate fungal outbre

240 tal pain among patients who are on long-term voriconazole therapy is highly suggestive of periostitis

241 in patients who received appropriate initial voriconazole therapy was 24% compared with 47% in those

242 o achieve a prompt diagnosis and to initiate voriconazole therapy.

243 itis, is a reported side effect of long-term voriconazole therapy.

244 tients have improved on receipt of empirical voriconazole therapy.

245 ole concentration for 26 patients undergoing voriconazole therapy.

246 omparative Aspergillus Study (GCAS) compared voriconazole to amphotericin B (AmB) deoxycholate for th

247 dy evaluated the independent contribution of voriconazole to the development of squamous cell carcino

248 here appears to be no benefit to adding oral voriconazole to topical antifungal agents in the treatme

249 atitis may benefit from the addition of oral voriconazole to topical natamycin, and physicians should

250 n EUCAST and CLSI results ranged from 96.9% (voriconazole) to 98.6% (fluconazole).

251 eased rate of perforation or TPK in the oral voriconazole-treated arm; however, this was not a statis

252 best spectacle-corrected visual acuity than voriconazole-treated cases (regression coefficient=0.18

253 Among voriconazole-treated cases, the voriconazole MIC did not

254 .4 points (95% CI, 1.9-14.9) higher than the voriconazole-treated group (P = .01).

255 1-8.5) higher than study participants in the voriconazole-treated group (P = .046).

256 Among patients with CAPA receiving voriconazole treatment (13 patients, 43%) A trend toward

257 istant A. fumigatus that was associated with voriconazole treatment failure in patients with invasive

258 belief for natamycin treatment compared with voriconazole treatment for filamentous cases as a group

259 r clinical and microbiological outcomes than voriconazole treatment for smear-positive filamentous fu

260 Of the 119 patients (49.6%) in the oral voriconazole treatment group, 65 were male (54.6%), and

261 levels, and was reversible on termination of voriconazole treatment.

262 ths were treated for 3 months with 200 mg of voriconazole twice daily, followed by observation for 9

263 Benefits of voriconazole use when prescribed to lung transplant reci

264 nths, and complication rates associated with voriconazole use.

265 decision support for setting breakpoints for voriconazole using Clinical Laboratory Standards Institu

266 fluconazole, itraconazole, posaconazole, and voriconazole) using CLSI methods.

267 Susceptibility against amphotericin B (AmB), voriconazole (VCZ), and natamycin (NAT) was determined u

268 After shifting the medical regimen to voriconazole via topical and systemic routes (1mg/ml and

269 ed to those receiving posaconazole (POS) and voriconazole (VOR) during the same time period.

270 itraconazole (ITC), posaconazole (POS), and voriconazole (VOR), was examined against seven Candida a

271 lytic than the FDA-approved antifungal agent voriconazole (VOR).

272 Recommended oral voriconazole (VRC) doses are lower than intravenous dose

273 , fluconazole (FLC), posaconazole (PSC), and voriconazole (VRC) for six rarer Candida species (819 st

274 es were obtained in possible IA treated with voriconazole vs AmB with the same magnitude of differenc

275 participants were randomized to receive oral voriconazole vs oral placebo; a voriconazole loading dos

276 .3) or worse were randomized to receive oral voriconazole vs oral placebo; all participants received

277 or the need for TPK was determined for oral voriconazole vs placebo (hazard ratio, 0.82; 95% CI, 0.5

278 .32 mm; P = .001) in eyes randomized to oral voriconazole vs placebo.

279 400 or worse were randomized to receive oral voriconazole vs placebo.

280 Voriconazole was 1 of 2 antifungal agents recommended fo

281 Fungal minimum inhibitory concentration for voriconazole was 4 microg/mL or greater for six of eight

282 Voriconazole was active against all Candida spp. except

283 Exposure to voriconazole was associated with increased risk of SCC o

284 tible to voriconazole, and hence aerosolized voriconazole was introduced around the third month postt

285 between 2002 and 2012 in patients treated by voriconazole was launched in France.

286 decreased the activity of antifungal agents; voriconazole was the most affected drugs followed by amp

287 Voriconazole was used to treat 61 patients (92%); 35 pat

288 ng hair loss among our patients treated with voriconazole, we sought to determine the prevalence and

289 EAs for amphotericin B and voriconazole were >90% for most potentially susceptible

290 ole levels varied, and CSF concentrations of voriconazole were approximately 50% those of serum.

291 Meropenem, piperacillin, and voriconazole were cleared by the continuous renal replac

292 when apical and basolateral posaconazole or voriconazole were combined.

293 Susceptibility testing to natamycin and voriconazole were performed according to Clinical and La

294 on and determination of MIC to natamycin and voriconazole were performed according to Clinical and La

295 MICs to natamycin and voriconazole were significantly different across all gen

296 lysis suggests that natamycin is superior to voriconazole when filamentous cases are analyzed as a gr

297 und improvement with natamycin compared with voriconazole, whereas there was almost no difference bet

298 Objective: To compare oral voriconazole with placebo in addition to topical antifun

299 avuconazole was well tolerated compared with voriconazole, with fewer study-drug-related adverse even

300 atients were treated with antifungal agents (voriconazole, with or without liposomal amphotericin B),